A Brief Analysis of Product Transformation Under the Major Trends in the Veterinary Pharmaceutical Industry
Release time：2026-01-14 17:15
Under the broad trend of veterinary pharmaceutical development, product innovation is exhibiting multi-dimensional characteristics.
Under the broad trend of veterinary pharmaceutical development, product innovation is exhibiting multi-dimensional characteristics.
Green transformation has become a core strategic direction. As policies promoting antibiotic-free livestock farming gain momentum, demand for green products such as traditional Chinese veterinary medicines and microecological preparations has surged. These products replace antibiotics with natural ingredients like plant extracts and probiotics, effectively controlling infectious diseases while significantly reducing the risk of drug residues. For example, a company in Sichuan has launched an “Antibiotic-Free Livestock Farming Technology Service Package” that integrates vaccines and probiotic products, helping farms reduce their use of antimicrobial drugs by 41% and thereby establishing a distinctive competitive edge in the regional market.
Biotechnology innovation is driving product upgrades. High-end products such as genetically engineered vaccines and monoclonal antibody drugs are accelerating their adoption. Take the pet healthcare sector as an example: Zoetis has developed a monoclonal antibody drug that targets nerve growth factor. By blocking pain signal transmission, this drug provides long-lasting relief from osteoarthritis pain in dogs and cats, with a single dose maintaining efficacy for up to three months, significantly improving medication adherence. These innovative products not only meet clinical needs but also redefine industry standards.
Market segmentation drives product specialization. The booming pet economy has given rise to niche segments such as deworming medications and drugs for treating chronic diseases. Haizheng Animal Health has focused on compound deworming tablets for cats, leveraging their cost-effectiveness and expanding distribution channels to achieve cumulative sales exceeding 45 million tablets, successfully replacing six imported products. Meanwhile, the increasing penetration of aquaculture vaccines is boosting demand for parasitic disease control products, with sales in coastal regions growing at an average annual rate of 40%, thus paving the way for regional enterprises to break through and gain a competitive edge.
Related News
Production Address: Industrial Cluster Zone, Bo’ai County, Jiaozuo City, Henan Province
Henan Province, Luohe City, Salt and Chemical Industry Park
Sales Address: Building B, Zhenghong Zhi Space, at the intersection of Huayuan Road and Yingcai Street, Huiji District, Zhengzhou City, Henan Province
General Manager
Sales Department:
Ministry of Foreign Trade
Tel: +86-19603710917 (WeChat)
Email: isabella@huirunyy.com
Copyright © Henan Huirun Pharmaceutical Co., Ltd. IPv6 supported.